NeuroOne Medical Technologies Corp (NMTC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
Research Workspace
Put NMTC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve at least $10.5M revenue in fiscal 2026: Comparison needs review.
View ThesisRevenue is growing steadily — about 51% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 4% on a typical day and fell roughly 86% in its worst 12-month stretch.
View RiskNMTC’s sales growth is the core claim, though recent financial performance is weak and risk is high. Revenue grew 16% year over year in Q3 FY2026, but NMTC reported a GAAP loss. NMTC trades at 0.8× sales versus the 2.9× peer median. The price reflects less growth than our forecast, despite the wide peer-multiple gap. Our model puts the next-quarter miss probability near 54%. The fiscal 2026 revenue pillar needs review; its comparison is unverified. Peer multiples imply a price about 83% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. NMTC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering NMTC (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NMTC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NMTC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put NMTC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Achieve at least $10.5 million product revenue in fiscal 2026
Revenue growth supports $10.5 million target for fiscal 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Lowered price target indicates reduced growth expectations.
Threatens: Achieve $10.5M revenue in fiscal 2026
Earnings miss indicates potential revenue challenges.

Advances: Achieve $10.5M revenue in fiscal 2026
Increased product orders support revenue growth objective.
